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triﬂuoroacetic acid; MIC, minimal inhibitory concentraThe cathelicidin derived human peptide LL37 has a broad spectrum of antimicrobial and immunomodu-
latory activities. The large variety of biological activities makes LL37 a very promising candidate for clin-
ical applications. The production of biologically active LL37 in large amounts with reduced costs can only
be achieved using recombinant techniques. In this work, LL37 has been cloned to the N- and C-termini of
a family III carbohydrate-binding module fused to the linker sequence (LK-CBM3) from Clostridium ther-
mocellum; both constructions (LL37-LK-CBM3 and LK-CBM3-LL37) were cloned into the pET-21a vector. A
formic acid recognition site was introduced between the two modules, allowing the isolation of LL37 after
chemical cleavage.
The recombinant proteins were expressed in Escherichia coli BL21 (DE3) and solubilized with Triton X-
100. The puriﬁcation was achieved using cellulose CF11 ﬁbers, taking advantage of the CBM3 speciﬁc
afﬁnity for cellulose; after hydrolysis with formic acid, LL37 was further puriﬁed by reverse-phase HPLC,
as conﬁrmed by MALDI-TOF mass spectrometry. The production and puriﬁcation methodology developed
in this work compares advantageously to other protocols previously described, having fewer puriﬁcation
steps. Only the recombinant LL37 obtained from the C-terminally fused protein (LK-CBM3-LL37) showed
antibacterial activity against E. coli K12, with a MIC of 180 lg/ml.
 2009 Elsevier Inc. All rights reserved.Introduction
The increasing resistance of microorganisms against common
antibiotics has become a growing threat for the public health. Anti-
microbial peptides (AMPs)1 are part of the innate immune system
and have a large spectrum of antimicrobial activities against Gram-
positive and Gram-negative bacteria, fungi [1] and viruses [2].
AMPs are generally deﬁned as cationic, amphipathic peptides, with
less than 50 amino acids, including multiple arginine and lysine
residues [3] and show inhibitory concentrations (MIC) as low as
0.25–4 lg/ml [2]. They are widely distributed in nature, from in-
sects to plants and animal species; over 1440 AMPs have been
identiﬁed so far (http://aps.unmc.edu/AP/main.php; July 2009).
In mammals, defensins and cathelicidins represent the two ma-
jor types of AMPs. Cathelicidins share a highly conserved N-termi-
nal cathelin domain, ﬂanked by a rather variable antimicrobial
peptide on the C-terminus [4]. The hCAP-18/LL37 is the only hu-
man cathelicidin. The antimicrobial peptide is referred to as LL37,ll rights reserved.
).
; CBM, carbohydrate-binding
merase chain reaction; TFA,
tion.since it has a 37 amino acids sequence starting with two leucines.
It is a 4.5 kDa, cationic (+6), amphipathic a-helical peptide, with a
broad spectrum of antimicrobial activity. LL37 and the precursor
protein, hCAP-18, can be found at different concentrations in many
different cells, tissues and body ﬂuids. Durr et al. [5] summarized
the various tissues where LL37 expression has been detected. Be-
sides its protective effect against infections, a variety of other bio-
logical activities have been described. In fact, LL37 induces
chemotaxis of mast cells [6], monocytes, T lymphocytes and neu-
trophils [7], promotes wound healing [8], angiogenesis and arterio-
genesis [9].
Many bacterial and fungal enzymes that hydrolyse insoluble
carbohydrates share a common structure composed of a catalytic
domain linked to a carbohydrate-binding module (CBM). CBMs
that are speciﬁc for insoluble cellulose (cellulose binding domain
– CBD) represent the predominant category. The CBMs can be
grouped into distinctive families on the basis of amino acid se-
quence similarities [10]; 53 families of CBMs have been recognized
so far (http://www.cazy.org/fam/acc_CBM.html; July 2009).
Family III CBDs normally comprise 150 amino acids residues,
have been identiﬁed in many different bacterial enzymes, and also
in non-hydrolytic proteins [11]. Clostridium thermocellum produces
a multi-enzyme complex of cellulases and hemicellulases, termed
the cellulosome, which is assembled by the scaffoldin protein CipA.
2 R. Ramos et al. / Protein Expression and Puriﬁcation 71 (2010) 1–7Binding of the cellulosome to the plant cell wall is driven by the ac-
tion of the CipA family 3 CBM (CBM3), which presents high afﬁnity
for crystalline cellulose [12]. CBM3 belongs to the all-b family of
proteins and is arranged in two antiparallel b sheets that form a
b sandwich with jellyroll topology [11].
In this work, we describe the successful cloning, expression and
puriﬁcation of LL37 using the CBM3 from C. thermocellum as fusion
partner. The CBM3 is overexpressed in Escherichia coli and it is pos-
sible to take advantage of its afﬁnity properties to purify recombi-
nant proteins on cellulose ﬁbers, reducing signiﬁcantly the costs of
puriﬁcation.Fig. 2. Flow chart for the expression and puriﬁcation of LL37 from E. coli.Materials and methods
Construction of expression vectors
The gene encoding CBM3 fused to the endogenous CipA N-ter-
minal linker sequence (LK) has previously been cloned in the
expression vector pET21-a (Novagen), in our laboratory [12]. Here,
two expression vectors were constructed with LL37, either at the
N-terminus (LL37-LK-CBM3) or C-terminus (LK-CBM3-LL37) of
the pET21-LK-CBM3 vector (Fig. 1).
The DNA fragment encoding LL37 was ampliﬁed by polymerase
chain reaction (PCR) from hCAP-18/pET15b generously provided
by Dr. Ole Sorensen, Lund University, Lund, Sweden. For the
LL37-LK-CBM3 construction, the following primers were used: 50-
GGA ATTC CAT ATG CTG CTG GGT GAT TTC TTC-30 (forward primer)
and 50-CTA GCT AGC CGG ATC GGA CTC TGT CCT GGG TAC-30 (re-
verse primer). For the LK-CBM3-LL37 construction, the primers
were: 50-CCG CTC GAG GAT CCG CTG CTG GGT GAT TTC TTC-30 (for-
ward primer) and 50-CCG CTC GAG TTA GGA CTC TGT CCT GGG
TAC-30 (reverse primer). NdeI, NheI (LL37-LK-CBM3) and XhoI
(LK-CBM3-LL37) recognition sites are shown in bold. In order to al-
low the chemical cleavage with formic acid, proline and aspartate
residues were introduced (in italic). PCRs were performed using
the DNA Polymerase VENT (Stratagene). The PCRs were performed
as follows: preheating at 95 C for 2 min, 30 cycles at 95 C for 30 s,
30 s at 52 C and 30 s at 72 C, followed by a ﬁnal elongation stage
at 72 C for 10 min. The ampliﬁed products were recovered from
1% agarose gel, digested with NdeI and NheI or XhoI and ligated into
pET21-LK-CBM3 plasmid and sequenced to ensure that no
mutations had occurred during the PCR. Fig. 1 represents LL37-
LK-CBM3 and LK-CBM3-LL37 constructions. The construction
LL37-LK-CBM3 kept the C-terminal His6-tag even though this tag
was not used for puriﬁcation.Expression and puriﬁcation of fusion proteins
Fig. 2 summarizes the strategy followed for the production and
puriﬁcation of recombinant LL37. The recombinant plasmids were
transformed into the E. coli strain BL21 (DE3) (Novagen) for protein
expression. The bacterial strains were grown in Luria–BertaniFig. 1. Schematic representation of LL37-LK-CBM3 (A) and LK-CBM3-LL37 (B)
constructions. The AspPro site for chemical cleavage with formic acid is shown in
black; H, His-tag.broth (LB) containing 100 lg/ml of ampicillin at 37 C to mid-expo-
nential phase (OD595 = 0.6). Expression of the fusion proteins was
initiated by adding isopropyl-b-D-thiogalactopyranoside (IPTG) at
a ﬁnal concentration of 1 mM and the culture was incubated over-
night at 37 C. The cells were centrifuged at 6000 rpm for 15 min at
4 C, resuspended in Tris–HCl pH 7.0, 20 mM NaCl, 5 mM CaCl2(2-
H2O) buffer (CBM buffer) and sonicated in ice for 6 min. After cen-
trifugation at 12,000 rpm, for 30 min at 4 C, the cells were
resuspended in CBM buffer with 1% Triton X-100. The cells were
centrifuged again at 12,000 rpm, for 30 min at 4 C and the soluble
fraction was collected.
The recombinant proteins were puriﬁed on cellulose CF11 (Sig-
ma), exploiting the CBM3 cellulose-binding properties, as follows:
20 ml of cell-free extractsweremixedwith 2 g of cellulose and incu-
bated, with agitation, for 1 h at 4 C. The cellulose with bound pro-
teins was then centrifuged and washed ﬁve times with CBM buffer.
Formic acid cleavage and LL37 puriﬁcation
In order to cleave LL37 of the recombinant protein, a 50% formic
acid solution (20 ml of distilled water and 26 ml 88% formic acid)
was applied directly to cellulose with the adsorbed fusion proteins.
The mixture was then incubated for 24 h at 50 C. The supernatant
was separated after centrifugation at 12,000 rpm, for 30 min, and
lyophilized to remove formic acid. The cleavage was conﬁrmed
by SDS–PAGE using a 16.5% Tris–Tricine gel.
The puriﬁcation of LL37 was achieved by reverse-phase HPLC,
using an YMC C18 preparative column (250  30 mm) equilibrated
with aqueous acetonitrile (5%)/0.1% triﬂuoroacetic acid (TFA). The
peptide was eluted using a linear gradient of acetonitrile from 5%
to 90% at a ﬂow rate of 5 ml/min. The elution was monitored at
215 nm. Several peaks were collected and analyzed by SDS–PAGE
using a 16% Tris–Tricine gel. The fraction corresponding to pure
LL37 was lyophilized. The concentration of the recombinant pep-
tides was quantiﬁed using Waddell’s method [13].
MALDI-TOF mass spectrometry
The purity of LL37 was conﬁrmed by mass spectrometry at the
Institute of Molecular Pathology and Immunology of the University
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using microC18 ZipTips (Millipore, USA) accordingly to the manu-
facturer’s protocol. The samples were eluted with the matrix a-cy-
ano-4-hydroxycinnamic acid (5 mg/mL) in 50% acetonitrile/0.1%
TFA and spotted onto a stainless steel 192-well MALDI plate. After
sample crystallization, mass spectrum acquisition was performed
using a 4700 Proteomics Analyzer MALDI-TOF/TOF (Applied Bio-
systems, USA). Mass spectra were acquired in positive linear mode
for 1–15 kDa (m/z) mass window and in positive reﬂector mode for
the ranges 700–7000, 4000–5000 and 4585–4600 Da (m/z). Exter-
nal calibration of the mass spectrum was performed using Applied
Biosystems Calibration Mix 3 standards.Fig. 4. Binding assay of LK-CBM3-LL37 on CF11 ﬁbers. Mw, protein molecular
weight marker; 1, Triton solubilized supernatant; 2, unbound protein; 3, ﬁrst
cellulose wash; 4, ﬁfth cellulose wash; 5, bound protein eluted with 1% SDS.Antibacterial activity
The antibacterial activity of the pure peptides was quantiﬁed in
96-well polypropylene microtiter plates, as described by Vogt and
Bechinger [14], with some modiﬁcations. E. coli strain K12 was
grown at 37 C in LB medium until mid-logarithmic phase
(OD600 = 0.5). The cells were then resuspended in LB at 1  106
and 1  105 cells/ml; 100 ll of peptides, at different concentra-
tions, were inoculated with 50 ll of bacterial suspension, incu-
bated overnight at 37 C and the bacterial growth was assessed
by the measurement of optical density at 620 nm. The results were
conﬁrmed by plating 25 ll aliquots of the mixture from each well
in LB plates and incubating for 16 h at 37 C, followed by colony
counting. Each assay was repeated three times and controls were
made by adding sterile deionized water, instead of the peptide
solutions. The minimal inhibitory concentration (MIC) was deter-
mined as the lowest peptide concentration that inhibited bacterial
growth.Results and discussion
Expression and puriﬁcation of recombinant proteins
The protein LL37 was successfully cloned at both the N- and C-
terminus of the LK-CBM3 in the expression vector pET21-a. After
transformation of the recombinant plasmids into E. coli BL21
(DE3), several fermentation conditions were tested, attempting to
optimize the production of the recombinant proteins in the soluble
form. The following operational parameters and E. coli strains were
varied or tested: concentration of IPTG, induction temperature andFig. 3. Expression of recombinant proteins LL37-LK-CBM3 and LK-CBM3-LL37. Mw,
protein molecular weight marker; 1, LL37-LK-CBM3 insoluble fraction; 2, LL37-LK-
CBM3 soluble fraction; 3, LL37-LK-CBM3 Triton X-100 solubilized fraction; 4, LK-
CBM3-LL37 insoluble fraction; 5, LK-CBM3-LL37 soluble fraction; 6, LK-CBM3-LL37
Triton X-100 solubilized fraction.time, fermentation in M9 minimal medium, transformation into
E. coli Tuner (DE3) and Origami (DE3) and co-expression with
chaperones GroEL–GroES and E. coli trigger factor (TF) [15]. Only
using the nonionic detergent, Triton X-100, the production of the
proteins (27 kDa) in the soluble form was achieved (Fig. 3).
In previous work, Guerreiro et al. [12] reported the expression of
the same CBM3 from C. thermocellum used in this work. The CBM,
fused or not with small antimicrobial peptides, was overexpressed
in the soluble form. Only the protein LKLLKKLLKLLKKLGGGK-LK-
CBM3 was found to be insoluble when expressed by different
E. coli strains, under a range of induction conditions. In this work,
the CBM3 fused to LL37 could only be solubilized with detergents.
The use of CBM3 as fusion partner had two major goals: (1) to ex-
press and purify the peptide LL37 by a novel, fast and inexpensive
method, using cellulose for puriﬁcationand (2) tomodify the surface
of cotton fabricswithLL37, aimingatobtaining textileswithantibac-
terial and bioactive properties. As already stated, LL37 is an antimi-
crobial peptide but it also has a broad spectrum of biological
activities. Thus, one main objective was to modify cellulose for bio-
medical applications.However, in thiswork,we focuson theproduc-
tion of the isolated LL37. For this purpose, the CBM is still useful,Fig. 5. Formic acid cleavage and release of LL37. Mw, protein molecular weight
marker; 1, insoluble fraction of cleaved LL37-LK-CBM3; 2, supernatant of cleaved
LL37-LK-CBM3; 3, insoluble fraction of cleaved LK-CBM3-LL37; 4, supernatant of
cleaved LK-CBM3-LL37.
Fig. 6. (A) Reverse-phase HPLC chromatogram of fusion proteins LL37-LK-CBM3 and LK-CBM3-LL37. (B) RP-HPLC peak fractions.Mw, protein molecular weight marker; lanes
1–4, peak fractions of cleaved LL37-LK-CBM3; lanes 5–8, peak fractions of cleaved LK-CBM3-LL37.
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pensive afﬁnity-based separation, using cellulose ﬁbers.
The puriﬁcation of the LL37-LK-CBM3 and LK-CBM3-LL37 re-
combinant proteins was performed on cellulose CF11 ﬁbers. The
family III CBM from C. thermocellum is well studied. This CBM ad-
sorbs to cellulose with high afﬁnity constants [16]. The fusion with
LL37 and the presence of residual detergent did not affect the bind-
ing of the CBM3 on CF11 cellulose. Fig. 4 shows a binding assay of
the LK-CBM3-LL37 recombinant protein, performed as described
previously [12]. The recombinant proteins bind very efﬁciently to
cellulose and only desorb using SDS.
To date, few groups have reported the recombinant expression
of LL37 either in the E. coli expression system [17–19] or in the
Pichia pastoris system [20]. In these publications, the puriﬁcation
of the recombinant proteins is always performed through afﬁnity
chromatography techniques, using expensive matrixes (sepharose,
cobalt). Although very effective, chromatography is a slow process
with high costs. LL37 is a peptide with a large potential for biomed-ical applications. Thus, the production of large amounts of LL37 at
low costs is of great importance, puriﬁcation being generally the
most critical step in this regard. Cellulose is cheap and available
in many forms. Therefore, the expression system using the CBM3
as the expression and puriﬁcation module is very attractive. As
shown previously [12] and in this work, the CBM3, when fused
to antimicrobial peptides, is overexpressed in E. coli conserving
its binding properties. The adsorption of CBM3 on cellulose is quite
fast, allowing the recombinant proteins to be puriﬁed in a quick,
inexpensive method. Moreover, no columns and chromatography
units are required. Compared with previous publications, this
method is clearly the best for large-scale puriﬁcation of LL37.
Chemical cleavage and puriﬁcation of LL37
Several methods, both enzymatic (factor Xa and thrombin pro-
teases) and chemical (CNBr and formic acid) are widely used to
cleave proteins from fusion partners. Formic acid is a good option
Fig. 7. MALDI-TOF MS analysis of puriﬁed LL37. (A) M-LL37-D. (B) P-LL37. The measured molecular weights are very similar to the theoretical values (4739.6 and 4590.4 Da).
Fig. 8. Antibacterial activity of P-LL37 against E. coli K12. Bacterial growth was inhibited at a concentration of 180 lg/ml of P-LL37.
R. Ramos et al. / Protein Expression and Puriﬁcation 71 (2010) 1–7 5for large-scale production, due to its low cost. The chemical cleav-
age of the recombinant proteins was performed, in this work, with
50% formic acid, at 50 C for 24 h. LL37-LK-CBM3 and LK-CBM3-LL37 proteins were ﬁrst puriﬁed on cellulose. Then, formic acid
was applied directly on the CF11 ﬁbers with the bound protein.
After centrifugation, the supernatants were lyophilized to
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(Fig. 5). After acid hydrolysis and lyophilization, part of the protein
(mostly CBM) precipitates, probably degraded by the formic acid.
On the other hand, most of the peptide (4.5 kDa) remains soluble,
as shown in Fig. 5 (lanes 2 and 4). The precipitation of the CBM3
facilitates the puriﬁcation. In fact, LL37 is separated from most of
the CBM and other contaminating proteins by centrifugation. The
soluble supernatants, with a large proportion of LL37, were then
subjected to RP-HPLC to achieve higher purity (Fig. 6a). In this step,
the fractions corresponding to the major peaks were collected and
the purity of the peptides was checked on 16.5% Tris–Tricine gel
and conﬁrmed by MALDI-TOF. Fig. 6b presents the peak fractions
from RP-HPLC for the two fusion proteins. Lanes 4 and 8 demon-
strate the purity of the two peptides.
The two different proteins, both including the LL37, were ob-
tained after the formic acid cleavage of the CBM constructs. The
ﬁrst peptide, obtained by the cleavage of the LL37-LK-CBM3 pro-
tein, has 39 amino acids with a theoretical molecular weight of
4739.6 Da. It is ﬂanked with the N-terminal methionine, remaining
from the translation process and a C-terminal aspartic acid, left by
the chemical cleavage (M-LL37-D). Although 55–70% of mature
proteins are subjected to N-terminal Met excision [21], M-LL37-D
conserved the initial amino acid. Indeed, as demonstrated by Sher-
man et al. [22] most proteins retain the initial Met when the N-ter-
minus residue is leucine. The second peptide, cleaved from the LK-
CBM3-LL37 protein, is 38 amino acids long, with a theoretical
molecular weight of 4590.4 Da, having a proline residue at the N-
terminus (P-LL37). Mass spectrometry (Fig. 7) conﬁrmed the purity
of LL37 and the predicted molecular weights.
The production and puriﬁcation of LL37 using CBM3 as the fu-
sion partner only requires one chromatographic step. All previous
publications refer to at least two, and use enzymes to cleave LL37.
Li et al. [17,23] also use formic acid for chemical release of LL37,
however the puriﬁcation scheme used is more complex. In this
work, it was possible to obtain 1 mg of pure P-LL37 and 2 mg of
pure M-LL37-D from 1 L of bacterial culture. This yield is compara-
ble to the ones obtained in previous studies [17–19]. Li et al. [23]
also described a novel method to purify LL37 utilizing its property
of aggregation. The authors were able to produce 2.6 mg of recom-
binant LL37 from 1 L of culture. However, this method required
two cleavage steps with thrombin and formic acid and three puri-
ﬁcation steps.
Antibacterial activity
M-LL37-D and P-LL37 antibacterial activities were tested
against E. coli K12. The concentration of the peptides was quanti-
ﬁed by UV spectroscopy using the Waddell’s method [13]. Fig. 8
demonstrates that P-LL37 has antimicrobial activity, with a MIC
of about 180 lg/ml (40 lM), similar to the values found in the lit-
erature [5,17]. At lower concentration, P-LL37 inhibited bacterial
growth only partially. The peptide (M-LL37-D) obtained from the
N-terminal fusion construct (LL37-LK-CBM3) showed no antibacte-
rial activity. According to Nagaoka et al. [24], the N-terminus and
C-terminus of LL37 do not contribute to the formation of a-helical
structures, being less important for its antimicrobial activity. How-
ever, the C-terminal aspartic acid reduces the global charge of the
peptide. Furthermore, Giglione et al. [21] suggest that an N-termi-
nal Met may act as a destabilization signal. This peptide has a total
charge of +5, so the second hypothesis seems to be more likely. In
fact, other AMPs with lower net charge still exhibit antibacterial
activity. As already stated, recombinant LL37 has already been ex-
pressed and puriﬁed and E. coli but only two groups tested the anti-
bacterial activity of the pure peptides. Yang et al. [18] produced the
peptide GSLL-39 with a MIC of 12.5 lg/ml against E. coli DH5a and
25 lg/ml against S. aureus; Li et al. [17] obtained the peptide P-LL37 with a MIC of 180 lg/ml (40 lM) against E. coli K12. Durr
et al. [5] report that the MIC of LL37 against E. coli and S. aureus
is higher than 144 lg/ml (32 lM), similar to the P-LL37 expressed
previously and in this work (Fig. 8).
Conclusions
LL37 has been extensively studied in recent years. The variety of
immunological and antimicrobial activities makes LL37 a very
promising candidate for clinical applications. For these purposes,
high amounts of affordable LL37 can only be obtained using recom-
binant techniques. Major advances in solid-phase chemical synthe-
sis of peptides, over the last ﬁve years have rendered the large-
scale synthesis of long chain-length bioactive peptides possible,
but this technique is too expensive for the production of large
quantities of pure peptides with more than 30 amino acids. In this
work, the family III CBM from C. thermocellum was used as fusion
partner, taking advantage of its cellulose-binding properties for
puriﬁcation. The antibacterial assays showed that only P-LL37
was active. The methodology described in this work appears to
be very effective for production and puriﬁcation of AMPs. The
use of cellulose for puriﬁcation and formic acid for chemical cleav-
age make this method the more cost effective when comparing to
previous publications.
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